Nefopam Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablet / Injection
Available Strengths: 30 mg, 20 mg/2 mL
Reference Brands: Acupan (UK),
Category:
Pain Management
Nefopam Hydrochloride is available in Tablet / Injection
and strengths such as 30 mg, 20 mg/2 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nefopam Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nefopam Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nefopam hydrochloride is a benzoxazocine derivative classified as a non-opioid, non-steroidal, centrally acting analgesic. Developed in the 1960s and initially known as fenazocine, it was first investigated for its antidepressant properties before being recognized for its analgesic effects and subsequently renamed nefopam in 1970. Over time, it has gained clinical importance as an alternative option for pain management, particularly when opioid or NSAID therapy is not suitable.
Structurally, nefopam shows resemblance to antihistamines such as orphenadrine and diphenhydramine, although its pharmacological profile is distinct. The precise mechanisms underlying its analgesic action are complex and not yet fully understood. However, it is known to act centrally by modulating neurotransmitter pathways involved in pain perception, including inhibition of monoamine reuptake and modulation of excitatory neurotransmission.
Nefopam is commonly used for the management of moderate acute pain, postoperative pain, and certain chronic pain conditions. As it does not belong to the opioid or NSAID classes, it avoids many of the typical adverse effects associated with those groups, making it a valuable option in multimodal pain management strategies under appropriate medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing